 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
Username  karmastockContact Info No contact information available. Interests Network Interests No interests in network yet. | Sponsored Links My Media No media file selected. Recent Blog Entries 
Published On: 01-22-2012 09:09 PM
Blog Category: No Category Blog Tags: amex mdgn, anemia, biopump, epodure, european patent office, hcp, hemodure, hemophilia, hepatitis c, infradure, medgenics, mfc, nyse hcp, nyse mil, nyse rah, , ralcorp, skin biopsy, therapeutic proteins
Medgenics, Inc. (NYSE Amex:MDGN), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that the Company received notice of ‘Intention to Grant’ from the European Patent Office for the patent application entitled “USE OF DERMAL MICRO ORGANS,” with allowed claims covering a core element of its Biopump™ protein therapy technology. A counterpart patent in the United States was issued in December 2008, with rights extending to November 2023. The patent estate covering the Biopump includes compositions, methods of use and methods of manufacture, and includes issued patents in the United States, as well as pending applications in the United States and various foreign jurisdictions. Commenting on the European patent allowance, Andrew L. Pearlman, Ph.D., President and Chief Executive Officer of Medgenics, said: “We will be delighted to add this European patent to our growing intellectual property portfolio. This patent is important as it protects key elements of our protein production technology. These claims provide significant protection for our proprietary technology and create significant barriers of entry to any would-be competitors.” “Medgenics has pioneered the development of sustained production and delivery of therapeutic proteins using the patient's own intact tissue, which is a key differentiating factor of our technology. This patent, like its counterpart U.S. patent, is critical to protecting this unique tissue technology and its resulting protein production capabilities,” added Dr. Pearlman. Medgenics is developing and commercializing Biopump™, a proprietary tissue-based platform technology for the sustained production and delivery of therapeutic proteins using the patient's own skin biopsy for the treatment of a range of chronic diseases including anemia, hepatitis C and hemophilia. Medgenics believes this approach has multiple benefits compared with current treatments, which include regular and costly injections of therapeutic proteins. ********************************************** HCP, Inc., (NYSE:HCP) will report its fourth quarter and year end financial results on Tuesday, February 14, 2012, before the open of trading on the New York Stock Exchange. The Company will also host a conference call and webcast at 9 a.m. Pacific Time (12 noon Eastern Time) that same day in order to review its financial performance and operating results for the fourth quarter and year ended December 31, 2011. HCP, Inc., an S&P 500 company, is a real estate investment trust (REIT) that invests primarily in real estate serving the healthcare industry in the United States. ********************************************** MFC Industrial Ltd. (NYSE:MIL) is pleased to announce that its Board of Directors has declared an annual cash dividend for 2012 of US$0.22 per common share. The dividend is 10% higher than the dividend paid in 2011, and, based on the closing price of $7.01 for the Company's common shares on December 31, 2011, represents a dividend yield of approximately 3.13%, compared to an annual dividend yield of approximately 2.51% for the NYSE Composite Index in 2011. MFC Industrial Ltd. is a global commodities supply chain company that sources and delivers commodities and materials to clients all over the world, with a special expertise on the financing and risk management aspects of the business. ********************************************** Ralcorp Holdings, Inc. (NYSE:RAH) announced that it has received a ruling from the Internal Revenue Service ("IRS"  confirming the tax-free nature of the distribution of at least 80 percent of the outstanding shares of common stock of Post Holdings, Inc. to Ralcorp shareholders and related transactions. Based on certain facts, assumptions, representations and undertakings set forth in the ruling, the ruling concludes that for U.S. federal income tax purposes, the separation of the Post cereals business will qualify as a tax-free distribution to Ralcorp and to the holders of common shares of Ralcorp (except in respect of cash received in lieu of fractional shares).Ralcorp produces Post branded cereals, a variety of private-brand foods sold under the individual labels of various grocery, mass merchandise and drugstore retailers, and frozen bakery products sold to in-store bakeries, restaurants and other foodservice customers. ******************************************************************************
0 Comments
| Rate Me About Me
Social Actions My Quotes No quotes to display. My Network |
